Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain…
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose…
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6…
The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and…
Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” ProjectMUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a…
SHANGHAI, Dec. 11, 2024 /PRNewswire/ -- On November 11, Syrebo showcased several innovative rehabilitation robot products at MEDICA 2024 in…
SHENZHEN, China, Dec. 10, 2024 /PRNewswire/ -- The 2024 PHBS-CJBS Global Pitch Competition, jointly hosted by Peking University HSBC Business School…
Groundbreaking thinkALS™ Tool Empowers Providers to Identify and Refer Patients Quicker ARLINGTON, Va., Dec. 10, 2024 /PRNewswire/ -- It can take…
NAF calls for increased awareness and advocacy around use of AI to prevent potential abuses SANTA ANA, Calif., Dec. 10,…
CHICAGO, Dec. 9, 2024 /PRNewswire/ -- MDClone, a leading data exploration and synthetic data company, is proud to announce that it…